SCHEMBL16702102

SCHEMBL16702102

C=CS(=O)(=O)N(CCn1nc(-c2cnc(OC)c(F)c2)c2c(N)ncnc21)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 6/20 0.46
EGFR P00533 4/20 0.46
LCK P06239 2/20 0.46
JAK3 P52333 2/20 0.46
ITK Q08881 2/20 0.46
PIK3CD O00329 5/20 0.41
FGFR1 P11362 6/20 0.40
FGFR2 P21802 6/20 0.40
FGFR3 P22607 6/20 0.40
MTOR P42345 4/20 0.40
FGFR4 P22455 4/20 0.40
HDAC1 Q13547 2/20 0.40
SRC P12931 3/20 0.40
PIK3CA P42336 3/20 0.40
PIK3CB P42338 3/20 0.40
PIK3CG P48736 3/20 0.40
PRKDC P78527 3/20 0.40
ABL1 P00519 2/20 0.40
HCK P08631 2/20 0.40
KDR P35968 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16702423 0.85 FGFR1 (0.55) BTKEGFRLCKJAK3ITK
SCHEMBL16701939 0.85 BTK (0.56) BTKEGFRLCKJAK3ITK
SCHEMBL16702052 0.84 PIK3CD (0.56) BTKEGFRLCKJAK3ITK
SCHEMBL16702183 0.83 BTK (0.52) BTKEGFRLCKJAK3ITK
SCHEMBL16701590 0.83 PIK3CD (0.56) BTKEGFRLCKJAK3ITK
SCHEMBL16701700 0.82 PIK3CD (0.51) BTKEGFRLCKJAK3ITK
SCHEMBL16701594 0.82 EGFR (0.47) BTKEGFRLCKJAK3ITK
SCHEMBL16701780 0.82 PIK3CD (0.59) BTKEGFRLCKJAK3ITK
SCHEMBL16702192 0.82 PIK3CD (0.63) BTKEGFRLCKJAK3ITK
SCHEMBL16701606 0.82 PIK3CG (0.54) BTKEGFRLCKJAK3ITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160272645-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2016-09-22 US claimed
WO-2015069441-A1 PYRAZOLO-, IMIDAZOLO- AND PYRROLO-PYRIDINE OR -PYRIMIDINE DERIVATIVES AS INHIBITORS O BRUTONS KINASE (BTK) MEDIVATION TECHNOLOGIES, INC. (US) 2015-05-14 WO claimed
US-20160272645-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2016-09-22 US disclosed
US-20160272645-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2016-09-22 US disclosed
WO-2015069441-A1 PYRAZOLO-, IMIDAZOLO- AND PYRROLO-PYRIDINE OR -PYRIMIDINE DERIVATIVES AS INHIBITORS O BRUTONS KINASE (BTK) MEDIVATION TECHNOLOGIES, INC. (US) 2015-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272645-A1 Heterocyclic Compounds and Methods of Use BTK, PIK3CD, PIK3CB BTK 1/4885EGFR 828/4885LCK 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.